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Vitamin D compounds have been used successfully to treat
secondary hyperparathyroidism for almost three decades.
Side effects of increased levels of serum calcium and
phosphate and potential complications have increasingly
been recognized as problematic, and this has become an
even more difficult clinical challenge with the desire to
capitalize on some of the pleiotropic effects of vitamin D.
Nonclassical nuclear vitamin D receptor (VDR) effects on the
cardiovascular system, kidneys, and immune system, with the
prospect of improved patient survival, have moved to center
stage. Selective vitamin D compounds with minimal effects
on mineral metabolism and with maximal cardiovascular and
renal benefits are now needed. New vitamin D compounds
already in clinical use, which have an improved side-effect
profile and differential nonclassical effects compared with
calcitriol, are limited to the three licensed pharmaceuticals—
paricalcitol, 22-oxacalcitriol, and doxercalciferol. Other
compounds are under early development and it is
anticipated that these novel therapeutic concepts will result
in new vitamin D therapies that will help to reduce the high
mortality rate patients with kidney disease experience.
Kidney International (2011) 79, 702–707; doi:10.1038/ki.2010.387;
published online 20 October 2010
KEYWORDS: activated vitamin D; cardiovascular disease;
hyperparathyroidism; kidney disease
Our understanding of the biology and clinical consequences
of disordered vitamin D metabolism in the context of chronic
kidney disease (CKD) has progressed over recent years.
Advances are being made on several fronts including clinical
epidemiology, therapeutic trials, laboratory science and the
development of ‘new’ and possibly enhanced compounds.
Conspicuously absent, however, have been good quality
prospective intervention studies with patient-level outcomes.
This review will focus on the therapy of CKD patients with
vitamin D compounds in the light of an emerging paradigm
shift that takes in to account ‘nonclassical’ as well as ‘classical’
vitamin D effects.
For the purpose of the following discussion, ‘old’ will refer
to the active compound, calcitriol (1a,25(OH)2D3), its pro-
drug alfacalcidol (1a-(OH)D3), or calcifediol (25(OH)D3).
‘New’ will include other vitamin D compounds currently in
use or in a pipeline, and which may possess enhanced
qualities that are clinically useful to patients. The terms
‘native vitamin D’, ‘vitamin D’, and ‘cholecalciferol’ will
be regarded as synonymous, unless stated otherwise, and
will refer to cholecalciferol (vitamin D3) or ergocalciferol
(vitamin D2). ‘Active vitamin D’ refers to compounds that
directly activate the nuclear vitamin D receptor (VDR).
The group of ‘new’ vitamin D compounds already in
clinical use remains quite small, comprising paricalcitol
(19-nor-1a,25(OH)2D2), 22-oxacalcitriol, or maxacalcitol
(22-oxa-1a,25(OH)2D3) and doxercalciferol (1a-(OH)D2)
(Figure 1). None is new in the strict sense—most of them
have been in clinical use for a decade or more. Paricalcitol
and 22-oxacalcitriol bind directly to the VDR and are,
therefore, active compounds, whereas the third, doxer-
calciferol, is analogous to alfacalcidol, a prodrug for 1,
25-dihydroxyvitamin D2 that needs an enzymatic 25-hydro-
xylation activation step in the liver.
VITAMIN D AND MINERAL METABOLISM IN CKD
Of the myriad metabolic components of moderate and
advanced CKD, failure of renal bioactivation of 25-hydroxy-
cholecalciferol is a prominent and extremely well-studied
feature. Relative failure of this metabolic step, and conse-
quent sabotage of the endocrine vitamin D hormonal system,
is demonstrable early in the progression of CKD, and in
advanced CKD, severe deficiency of circulating calcitriol with
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failure of the vitamin D endocrine system is the norm.1 As is
the case with, for example, thyroid or adrenal insufficiency,
physiological replacement of the deficient active hormone is
associated with readily apparent and generally advantageous
responses. Despite this apparently simple paradigm, a recent
meta-analysis painted a surprisingly negative picture of
the utility of active vitamin D compounds, particularly in
patient-level outcomes and control of biochemical param-
eters,2 although this analysis has been the subject of some
criticism and the view of most nephrologists, supported by
two recent Cochrane reviews, is that treatment of hyper-
parathyroidism with active vitamin D compounds is logical
and generally effective.3–5
It is important to remind ourselves that over the last few
decades, product development has focussed mainly on the
classical endocrine actions of active vitamin D compounds
mediated through the principle target tissues, intestine, bone,
and parathyroid gland. The three new compounds already in
use have all been developed and marketed on the basis of
enhanced efficacy and/or reduced toxicity compared with
calcitriol. Here, the picture is a very mixed one. Two of these
compounds, namely 22-oxacalcitriol6 and paricalcitol,7
showed considerable promise during early testing in experi-
mental laboratory systems. In the case of 22-oxacalcitriol,
dramatically reduced calcemia with maintenance of potent
downregulation of the parathyroid gland was seen in vitro
and in animal models. In the case of paricalcitol, less striking,
but still significant, advantages were observed, particularly
with regard to a reduction of the tendency to elevate plasma
phosphate during treatment of rodents. On this background,
it was both surprising and disappointing to note the
complete failure of 22-oxacalcitriol to outperform calcitriol
in comparative studies conducted in Japan—both appeared
equally effective and equally toxic.8,9 In the case of pari-
calcitol, comparison with calcitriol yielded some advantage,
as judged by predefined end points relating to efficacy and
toxicity, the results pointing to more rapid parathyroid
hormone reduction and fewer calcemic episodes in pari-
calcitrol-treated patients.10 However, no prospective, place-
bo-controlled, and blinded study involving 22-oxacalcitriol,
paricalcitol, or doxacalciferol has yet demonstrated addi-
tional patient-level benefits when compared with calcitriol.
Nor, for that matter, have any studies been published
showing that either calcitriol or alfacalcidol has an advantage
over the other, with respect to biochemical or clinical end
points. Further uncertainty arises, because no distinction
between low-dose physiological replacement of deficient
calcitriol and higher-dose pharmacological use of these
compounds in an attempt to treat established hyperparathy-
roidism has been made in these studies. Finally, it is
important to recognize that the published work on the use
of active vitamin D compounds in CKD at all levels has been
based on populations with a high prevalence of vitamin D
insufficiency or deficiency.
Vitamin D sufficiency in non-CKD populations is impor-
tant for the normal functioning of the vitamin D endocrine
system, involving terminal activation of vitamin D in
the kidney by the key enzyme, 25-hydroxyvitamin D
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1a-hydroxylase (CYP27B1). It is estimated that B5% of
serum prohormone 25(OH)D is used in the kidney for the
endocrine vitamin D system and 485% of serum 25(OH)D
is used by local target tissues for autocrine/paracrine
activation to calcitriol (Figure 1). In addition, the importance
of serum prohormone vitamin D sufficiency for patients
with CKD, with loss of kidney activation, has only
emerged recently, with the observation of a very wide tissue
distribution of VDR together with CYP27B1 in the same or
neighboring cells, and many nonclassical vitamin D effects
are attributed to this paracrine/autocrine vitamin D system,
which is still functional in CKD patients. Vitamin D
sufficiency, quantified by serum 25-hydroxyvitamin D, is
therefore likely to be advantageous to our CKD population
and should be one of the first therapeutic interventions when
renal function deteriorates.
In this context, it is important to emphasize that both, the
local and endocrine vitamin D systems, are working together.
This has been nicely illustrated with monocytes from CKD
patients. These monocytes demonstrated a 50% lower
25(OH)D uptake compared with cells from patients with
normal renal function. This reduced cellular access of
25(OH)D to monocyte CYP27A1, with the consequence of
impaired paracrine/autocrine function, was corrected and
normalized after these CKD patients were treated with
calcitriol.11
VITAMIN D, CARDIOVASCULAR DISEASE, AND MORTALITY
One of the refreshing, but also very challenging, changes in
nephrology over the past decade has been the emphasis
placed on patient-level outcomes rather than surrogates. In
this respect, nephrology remains somewhat ‘behind the
curve’ compared with a number of other specialties, but
the emphasis is now very strong to the extent that the
credibility and acceptability of new therapies rests increas-
ingly heavily on these hard-to-demonstrate end points.
Conversely, it is because these end points are so hard to
demonstrate that the day of the surrogate has not yet passed
and nor has that of a number of different types of
retrospective analysis. The latter, in particular, have power-
fully influenced our thinking as to which clinical end points
are relevant to active vitamin D therapies. Perhaps surpris-
ingly, cardiovascular, rather than bone and mineral metabo-
lism outcomes, have come to the fore. This thinking has been
catapulted forward by studies showing effects of VDR gene
polymorphisms on mortality risk in hemodialysis patients12
followed by a series of very large historical cohort studies,
the first of which demonstrated that dialysis patients treated
with paricalcitol lived longer than did those treated with
calcitriol.13 This was quickly followed by other equally large
studies appearing to show a substantial survival advantage
among dialysis patients treated with injectable active vitamin
D compounds when compared with those not in receipt of
active vitamin D therapy.14 Doxercalciferol may also confer a
greater survival benefit than calcitriol, although similar to
that of paricalcitol.15 These early studies generally used
US patients treated with intravenous vitamin D compounds,
but more recently, a similar large historical cohort study was
conducted in South America in which enhanced survival was
again seen in active vitamin D-treated patients, this time in
using exclusively oral agents.16 Most of the previous studies
observed a survival advantage for any dosage compared
with no treatment with vitamin D compound. When the
association of incremental vitamin D dosages and survival
were analyzed, an apparent inverse dose–response effect were
observed, with paradoxically reduced survival at higher
administered vitamin D dosages.16,17 This seemingly counter-
intuitive observation may be due to confounding by medical
indication or consequence of vitamin D compound-mediated
altered soft tissue minerals. When the data were analyzed
using parathyroid hormone-adjusted vitamin D dosage, a
dose–response association between vitamin D compound and
survival was observed.18
Collectively, these observations are of great importance,
and, to date, no large retrospective study of this type has
found an increased mortality with VDR activation therapy.
Even so, confounding by intention, whereby unrecognized
bias between comparative groups is introduced, remains a
danger in studies of this type; however, even if they do not
conclusively establish the benefits suggested, they certainly
mount a persuasive case that makes it incumbent on the renal
community to generate appropriately powered and designed
prospective studies capable of providing definitive answers.
The focus on survival, largely mediated by the effects of
cardiovascular disease, has led to an enormous research
effort probing the mechanisms by which active vitamin D
compounds might affect the pathogenesis of arterial
function, vascular inflammation and calcification, cardiac
function, and blood pressure control. The relevant tissues all
express the nuclear VDR, which is bound by the three active
VDR ligands under discussion, as well as by the products
of the prodrugs, alfacalcidol and doxacalciferol, after
25-hydroxylation. Experimental models using knockout mice
missing either the VDR19,20 or the CYP27B1 enzyme with
resulting calcitriol deficiency,21 manifest a phenotype of
hypertension, left ventricular hypertrophy, and upregulation
of the renin–angiotensin–aldosterone system. In the case of
the CYP27B1 knockout, this phenotype can be rescued by
physiological replacement with calcitriol, although not by
correction of serum calcium and phosphorus by dietary
manipulation in the absence of calcitriol. Similar results were
observed in a salt-sensitive rat model, in which paricalcitol
therapy suppressed left ventricular hypertrophy and normal-
ized cardiac function.22
Experimental mouse or rat models have also been used to
investigate the impact of vitamin D compounds on vascular
calcification and loss of arterial elasticity, processes often
occurring in patients with CKD and particularly in those on
dialysis. In these CKD models, treatment with paricalcitol
produced less arterial calcification than calcitriol, although
more than a calcimimetic agent in 5/6 nephrectomized rats
with secondary hyperparathyroidism.23
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Mechanistically, there may be direct effects on cells of the
artery wall by modulation of the cellular responses and
transformation triggered by uremia, or indirect effects from
modulation of intestinal mineral absorption and mineral
buffering or release from the bone.24 Observational studies
support this beneficial role of vitamin D, and a double-
blind randomized study using paricalcitol is now testing
the hypothesis that active vitamin D treatment leads to
the regression of left ventricular cardiac hypertrophy
(PRIMO study, http://www.clinicaltrials.gov, NCT00497146
and NCT00616902).
VITAMIN D AND RENAL PROTECTION
Improvement of proteinuria and renal inflammation is
considered an important determinant of cardiovascular and
renal outcome. Animal studies with vitamin D compounds
have found improvement of proteinuria and inhibition of
renal inflammation, similar to that seen with inhibition of
the renin-angiotensin-aldosterone system with angiotensin-
converting enzyme or angiotensin II receptor blockade and
consistent with evidence that renin expression is suppressed
by VDR activation. Some preliminary clinical studies using
paricalcitol support these observations, and a prospective
double-blind, randomized, placebo-controlled study investi-
gating above hypothesis, the effect of paricalcitol in
addition to renin-angiotensin-aldosterone system blockade
on diabetic proteinuria, is due to be published shortly
(VITAL study, NCT00421733).
ARE ACTIVE VITAMIN D COMPOUNDS SAFE?
The most obvious side effects of VDR activators in clinical
use are increased levels of serum calcium and phosphate and
oversuppression of parathyroid hormone. Biologically, the
endocrine role of VDR activation is primarily to regulate
calcium balance, and CKD is associated with hypocalcemia.
Of concern in CKD is that such changes are meeting a
malfunctioning biological system, already unable to keep
calcium in solution. The concerns about altered minerals are
excess soft tissue and vascular calcification and their link to
adverse outcome. However, this effect is mirroring the
endocrine effect of VDR activation, is likely linked to other
factors, and is dose dependent.
CAN TISSUE SELECTIVITY BE ACHIEVED?
The increased understanding of VDR-mediated biological
effects, with the changing therapeutic paradigms, raises the
question, how tissue selectivity is achieved and how this
could be used therapeutically? The VDR is also expressed in
tissues not directly involved in calcium homeostasis, provid-
ing means for the nonclassical effects of vitamin D. An
important question is if and how tissue or cell selectivity is
achieved by the endogenous vitamin D system and how the
effect of active VDR ligands could differ from one another
and, perhaps, between tissues as well.25,26 The key vitamin D-
activating enzyme, CYP27B1, is expressed and differentially
regulated in VDR-expressing target tissues, complementing
the endocrine system and enabling local calcitriol synthesis,
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depending on tissue-specific requirements (Figure 2). Activa-
tion of the catabolic enzyme 24-hydroxylase (CYP24A1) in
target tissue provides another point for regulation and
may protect cells from excessive VDR activation. CYP27B1,
CYP24A1, the vitamin D binding protein in the blood,
intracellular vitamin D binding protein, vitamin D mem-
brane binding protein affinity for the vitamin D compound,
and alteration of the nuclear transcription factory are other
mechanisms that could enable tissue selectivity of vitamin D
compound.27 For example, differential tissue effects observed
with 19-nor compounds, such as paricalcitol, resulting in
less calcemia, is likely caused by differential nuclear
VDR coactivator and corepressor recruitment with altered,
tissue-specific target gene activation and inhibition.
OTHER VITAMIN D COMPOUNDS: WHAT’S IN THE PIPELINE?
The pharmaceutical industry has a large number of vitamin
D compounds and analogs ‘on the shelf ’. Some of these have
been examined as potentially enhanced treatments for
mineral disturbances in patients with CKD, although much
greater interest has focused on the possibility that these
agents may exert antiproliferative effects useful in oncology
and dermatological conditions without the calcemic toxicity
associated with calcitriol. There is considerable scientific
plausibility to this approach, which has certainly borne fruit
in the case of calcipotriol, widely used in the treatment
of psoriasis. The hope that one or more of these vitamin D
compounds would prove effective in the treatment of
malignancy has, however, not yet been realized.
Activation of the catabolic enzyme, CYP24A1, in target
tissue is an additional regulator of VDR activation and its
potential consequences. Although this enzyme is potentially a
treatment-limiting factor for all the vitamin D compounds in
clinical use, it is also a potential therapeutic target. New
compounds under development with dual action, namely
activation of the VDR and simultaneous inhibition of
CYP24A1, are in phase II clinical investigation.
NEW COMPOUNDS FOR NATIVE VITAMIN D DEFICIENCY
Vitamin D insufficiency is highly prevalent amongst the
general healthy population in temperate climates, and yet
more so in patient groups manifesting chronic disease.1,28,29
Those with CKD are no exception, with prevalence rates of
vitamin D insufficiency in the order of 75% and of vitamin D
deficiency in the order of 30%. There is a convergence of
epidemiological data, basic cell biology, and physiological
plausibility that points to a wide range of ‘nonclassical’
effects of vitamin D compounds that can only be properly
subserved by provision of one of the precursors rather than
of the active hormonal form itself.30,31 This is possible
because most cells that express the VDR and are vitamin
D-responsive also express their own differentially regulated
cellular CYP27A1 machinery, in effect allowing calcitriol to
be ‘locally produced for local need’. It is on this background
that recent reports of new compounds designed to perform
the same role as native vitamin D are arousing interest.
These compounds, some of which require bioactivation by
one or more hydroxylations, may differ from native vitamin
D in a number of ways, including altered pharmacokinetics
and capacity to upregulate or downregulate catabolic and
other involved enzymes. Whether these differences are in any
way tissue specific remains to be seen; if they are, there is
considerable potential for therapeutic enhancement.
CONCLUSIONS AND RECOMMENDATIONS
Although the appearance of new active vitamin D compounds
is limited to three licensed pharmaceuticals, all of which have
been in routine clinical use for several years, many others lurk
in the wings. Despite the paucity of new available compounds
available for clinical testing, both clinical and laboratory
investigation of the vitamin D compounds continues apace.
Importantly, with the changing therapeutic paradigms that
have emerged over recent years, vitamin D compounds now
have a real prospect of improving patient outcome.
However, we believe that the endemic vitamin D
insufficiency/deficiency in CKD populations has been largely
ignored. It is critical that future studies of active vitamin D
compounds, as well as calcimimetics, should be designed to
take into account the high prevalence of native vitamin D
insufficiency by first correcting this or including a native
vitamin D treatment arm as a positive control.
Whether or not the newer compounds genuinely enhance
patient outcomes continues to be a matter of intense
debate—the arrival of additional new compounds, both
active and precursors, will further stimulate that debate and
perhaps result in the substantial advances that have been
lacking in recent years.
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